The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012
Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives Source: Eur Respir J 2004; 24: Suppl. 48, 185s Year: 2004
Long term macrolide antibiotics for the treatment of bronchiectasis in adults - individual participant data meta-analysis Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019
The side effects of anti-tuberculosis treatment: a retrospective analysis Source: Eur Respir J 2002; 20: Suppl. 38, 369s Year: 2002
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019 Year: 2019
Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data Source: ERJ Open Res, 3 (2) 00085-2016; 10.1183/23120541.00085-2016 Year: 2017
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020
First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003
GRACE-01 Genomics to combat resistance against antibiotics in community-acquired LRTI in Europe – a multicentre, observational cohort study of cough/LRTI in primary care Source: Annual Congress 2007 - Clinical trial: antibiotic use in the community Year: 2007
Whom are we treating with adaptive servo-ventilation? - a clinical post-hoc analysis Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017
Comparative prospective cohort study of the efficacy and safety according to dose of Ceftriaxone in community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021
Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial Source: ERJ Open Res, 7 (4) 00418-2021; 10.1183/23120541.00418-2021 Year: 2021
Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020